scheduled between approximately 10:30 a.m. and 11:30 a.m. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before January 21, 1998, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Closed Committee Deliberations: On January 28, 1998, from 9:30 a.m. to 10 a.m., the meeting will be closed to permit discussion and review of trade secret and/or confidential information (5 U.S.C. 552b(c)(4)). FDA staff will present to the committee confidential information regarding present or future issues.

FDA regrets that it was unable to publish this notice 15 days prior to the January 28, 1998, Hematology and Pathology Devices Panel of the Medical Devices Advisory Committee meeting. Because the agency believes there is some urgency to bring this issue to public discussion and qualified members of the Hematology and Pathology Devices Panel of the Medical Devices Advisory Committee were available at this time, the Commissioner concluded that it was in the public interest to hold this meeting even if there was not sufficient time for the customary 15-day public notice.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: January 8, 1998.

#### Michael A. Friedman,

Deputy Commissioner for Operations. [FR Doc. 98–882 Filed 1–9–98; 2:15 pm] BILLING CODE 4160–01–F

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). At least one portion of the meeting may be closed to the public.

Name of Committee: General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee. General Function of the Committee: To provide advice and recommendations to the agency on FDA regulatory issues.

Date and Time: The meeting will be held on January 29, 1998, 8:45 a.m. to 6 p.m., and January 30, 1998, 8:45 a.m. to 1:30 p.m.

Location: Gaithersburg Marriott Washingtonian Center, 9751 Washingtonian Blvd., Salons F and G,

Gaithersburg, MD.

Contact Person: Gail G. Gantt, Center for Devices and Radiological Health (HFZ–410), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301–594–3090, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 12519. Please call the Information Line or access the Internet address of http://www.fda.gov.cdrh for up-to-date information on this meeting.

Agenda: On January 29, 1998, the committee will discuss, make recommendations, and vote on one premarket approval application (PMA) for a wound dressing for use on diabetic foot ulcers and a second PMA for a wound dressing for use on venous stasis ulcers. On January 30, 1998, the committee will discuss, make recommendations, and vote on a PMA for a skin adhesive for wound edge approximation.

approximation. *Procedure*: On January 29, 1998 from 8:45 a.m. to 10 a.m and from 11 a.m. to 6 p.m., and on January 30, 1998, from 8:45 a.m. to 1:30 p.m., the meeting is open to the public. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by January 22, 1998. Oral presentations from the public will be scheduled between approximately 8:45 a.m. and 9:45 a.m. on January 29 and 30, 1998. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before January 22, 1998, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Closed Presentation of Data: On January 29, 1998, from 10 a.m to 11 a.m. the meeting may be closed to permit discussion and review of trade secret and/or confidential information presented by the PMA sponsor(s) (5 U.S.C. 552b(c)(4)).

FDA regrets that it was unable to publish this notice 15 days prior to the

January 29 and 30, 1998, General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee meeting. Because the agency believes there is some urgency to bring this issue to public discussion and qualified members of the General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee were available at this time, the Commissioner concluded that it was in the public interest to hold this meeting even if there was not sufficient time for the customary 15-day public notice.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C., app. 2).

.s.c., app. 2).

Dated: January 8, 1998.

#### Michael A. Friedman,

Deputy Commissioner for Operations. [FR Doc. 98–887 Filed 1–9–98; 1:52 pm] BILLING CODE 4160–01–F

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

## Vaccines and Related Biological Products Advisory Committee; Notice of Meeting

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). At least one portion of the meeting will be closed to the public.

Name of Committee: Vaccines and Related Biological Products Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA regulatory issues.

Date and Time: The meeting will be held on January 30, 1998, 8 a.m. to 5 p.m.

Location: Holiday Inn, Versailles Ballrooms I and II, 8120 Wisconsin Ave., Bethesda, MD.

Contact Person: Nancy T. Cherry or Denise H. Royster, Center for Biologics Evaluation and Research (HFM–21), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852, 301–827–0314, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 12391. Please call the Information Line for upto-date information on this meeting.

Agenda: The committee will discuss the influenza virus vaccine formulation for 1998 and 1999. The committee will